SWOG clinical trial number
CTSU/EA2201

A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

Open
Phase
II
Abbreviated Title
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Status Notes
May Thet Cho, MD SWOG Champion
Activated
05/13/2021

Research committees

Gastrointestinal Cancer

Treatment

Ipilimumab Nivolumab

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unity (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/EA2201
SWOG Clinical Trial Number
CTSU/EA2197

Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

Research Committee(s)
Gastrointestinal Cancer
Activated
12/22/2020
Open
Phase
II-III